

105TH CONGRESS  
1ST SESSION

# H. R. 2407

To reauthorize the Office of National Drug Control Policy, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 4, 1997

Mr. LEVIN (for himself, Mr. RAMSTAD, Mr. BARRETT of Wisconsin, Mr. LATHAM, Mr. RANGEL, Mr. BLAGOJEVICH, and Mr. CUMMINGS) introduced the following bill; which was referred to the Committee on Government Reform and Oversight, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To reauthorize the Office of National Drug Control Policy,  
and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE AND REFERENCE.**

4 (a) SHORT TITLE.—This Act may be cited as the  
5 “Office of National Drug Control Policy Reauthorization  
6 Act of 1997”.

7 (b) REFERENCE.—Whenever in this Act an amend-  
8 ment or repeal is expressed in terms of an amendment

1 to, or repeal of, a section or other provision, the reference  
2 shall be considered to be made to a section or other provi-  
3 sion of the National Narcotics Leadership Act of 1988.

4 **SEC. 2. REAUTHORIZATION OF OFFICE OF NATIONAL DRUG**  
5 **CONTROL POLICY.**

6 (a) DEFINITIONS.—

7 (1) Section 1010 (21 U.S.C. 1507) is placed be-  
8 fore section 1002, is redesignated as section 1001A,  
9 and the heading for the section is amended to read  
10 as follows:

11 **“SEC. 1001A. DEFINITIONS.”.**

12 (2) Section 1001A, as redesignated, is amend-  
13 ed—

14 (A) by redesignating paragraphs (5)  
15 through (8) as paragraphs (7) through (10), re-  
16 spectively;

17 (B) by redesignating paragraphs (2)  
18 through (4) as paragraphs (3) through (5), re-  
19 spectively;

20 (C) by striking paragraph (1) and insert-  
21 ing the following:

22 “(1) the term ‘Office’ means the Office of Na-  
23 tional Drug Control Policy;

24 “(2) the term ‘drug’ has the same meaning as  
25 the term controlled substance has in section 102(6)

1 of the Controlled Substances Act (21 U.S.C.  
2 802(6));

3 (D) in paragraph (3), as redesignated, by  
4 inserting “, including activities to reduce the  
5 underage use of tobacco or alcoholic beverages”  
6 after “demand reduction”;

7 (E) in paragraph (4), as redesignated—

8 (i) by striking “enforcement” after  
9 “any”;

10 (ii) by striking “supply” and inserting  
11 “availability” after “reduce the”; and

12 (iii) in subparagraph (B) striking “en-  
13 forcement” after “drug”;

14 (F) in paragraph (5), as redesignated—

15 (i) by striking “demand for” and in-  
16 serting “use of” before “drugs”;

17 (ii) by inserting “drug abuse” after  
18 “including”;

19 (iii) in subparagraph (A), by striking  
20 “drug abuse”;

21 (iv) in subparagraph (D), by striking  
22 “and” at the end;

23 (v) by adding at the end the following:

24 “(F) drug-free workplace programs; and”;

25 and

1 (vi) by adding at the end the follow-  
2 ing:

3 “(G) drug testing;”;

4 (G) by inserting after paragraph (5), as re-  
5 designated, the following:

6 “(6) the term ‘intergovernmental relations’  
7 means domestic activities conducted by a National  
8 Drug Control Program agency that are intended to  
9 reduce the availability and use of drugs, including—

10 “(A) coordination and facilitation of Fed-  
11 eral, State, and local law enforcement drug con-  
12 trol efforts;

13 “(B) promotion of coordination and co-  
14 operation among the drug supply reduction and  
15 demand reduction agencies of the various  
16 States, territories, and units of local govern-  
17 ment; and

18 “(C) such other cooperative governmental  
19 activities which promote a comprehensive ap-  
20 proach to drug control at the National, State,  
21 territory, and local levels.”; and

22 (H) in paragraph (10), as redesignated,  
23 by—

24 (i) inserting “and ‘Strategy’” after  
25 “National Drug Control Strategy”;

- 1 (ii) by striking “means” and inserting  
2 “mean”; and  
3 (iii) striking “a” and inserting “the”  
4 after “means”.

5 (b) ESTABLISHMENT OF OFFICE OF NATIONAL  
6 DRUG CONTROL POLICY.—Section 1002 (21 U.S.C.  
7 1501) is amended—

8 (1) by amending subsection (a) to read as fol-  
9 lows:

10 “(a) ESTABLISHMENT OF OFFICE.—There is estab-  
11 lished in the Executive Office of the President the “Office  
12 of National Drug Control Policy” that—

13 “(1) develops national drug control policy;

14 “(2) coordinates and oversees its implementa-  
15 tion;

16 “(3) assesses and certifies the adequacy of na-  
17 tional drug control programs and budgets; and

18 “(4) evaluates their effectiveness.”;

19 (2) by amending subsection (b) to read as fol-  
20 lows:

21 “(b) DIRECTOR AND DEPUTY DIRECTORS.—

22 “(1) There shall be at the head of the Office of  
23 National Drug Control Policy a Director of National  
24 Drug Control Policy.

1           “(2) There shall be in the Office of National  
2 Drug Control Policy a Deputy Director of National  
3 Drug Control Policy, who shall assist the Director in  
4 carrying out the responsibilities of the Director  
5 under this Act.

6           “(3) There shall be in the Office of National  
7 Drug Control Policy a—

8           “(A) Deputy Director for International  
9 Drug Policy, who shall be responsible for the  
10 activities described in subparagraphs (A), (B),  
11 and (C) of section 1001A(4);

12           “(B) Deputy Director for Demand Reduc-  
13 tion Policy, who shall be responsible for the ac-  
14 tivities described in section 1001A(5); and

15           “(C) Deputy Director for Intergovern-  
16 mental Relations, who shall be responsible for  
17 the activities described in paragraphs (4)(D)  
18 and (6) of section 1001A.”;

19           (3) by striking subsection (c) and redesignating  
20 subsection (d) as subsection (e); and

21           (4) by adding at the end the following:

22           “(d) OFFICE OF NATIONAL DRUG CONTROL POLICY  
23 GIFT FUND.—There is established in the Treasury a fund  
24 for the receipt of gifts, both real and personal, for the  
25 purpose of aiding or facilitating the work of the Office

1 under section 1003(e). The Office is authorized to accept,  
2 hold, administer, and, solely to encourage funding for con-  
3 ferences, solicit contributions to the fund. Amounts depos-  
4 ited in the fund are authorized to be appropriated, to re-  
5 main available until expended for authorized purposes at  
6 the discretion of the Director. The Director is required  
7 to establish written rules setting forth the criteria to be  
8 used in determining whether the solicitation and accept-  
9 ance of real and personal gifts pursuant to this subsection  
10 would reflect unfavorably upon the ability of the Office  
11 of National Drug Control Policy or any employee to carry  
12 out its responsibilities or official duties in a fair and objec-  
13 tive manner, or would compromise the integrity, or the  
14 appearance of the integrity, of its programs or of any offi-  
15 cial involved in those programs.”.

16 (c) APPOINTMENT AND DUTIES OF DIRECTOR AND  
17 DEPUTY DIRECTORS.—Section 1003 (21 U.S.C. 1502) is  
18 amended—

19 (1) by amending the section heading to read as  
20 follows:

21 **“SEC. 1003. APPOINTMENT AND DUTIES OF DIRECTOR AND**  
22 **DEPUTY DIRECTORS.”;**

23 (2) in subsection (a)—

24 (A) in paragraph (1)—

1 (i) by inserting “the Deputy Director”  
2 after “The Director,”;

3 (ii) by inserting “Policy” after “De-  
4 mand Reduction”;

5 (iii) by striking “Deputy Director for  
6 Supply Reduction” and inserting “Deputy  
7 Director for International Drug Policy”;  
8 and

9 (iv) by striking “Associate Deputy Di-  
10 rector for National Drug Control Policy”  
11 and inserting “Deputy Director for Inter-  
12 governmental Relations”;

13 (B) by redesignating paragraphs (3) and  
14 (4) as paragraphs (5) and (6), respectively, and  
15 redesignating paragraph (2) as paragraph (4);  
16 and

17 (C) by inserting after paragraph (1) the  
18 following:

19 “(2) The Deputy Director shall—

20 “(A) carry out the duties and powers prescribed  
21 by the Director; and

22 “(B) serve as the Director in the absence of the  
23 Director or during any period in which the office of  
24 the Director is vacant.

1           “(3) In the absence of the Deputy Director, or if the  
2 office of the Deputy Director is vacant, the Director shall  
3 designate such other officer of the Office to serve as the  
4 Director if the Director is absent or unable to serve.”;

5           (D) in paragraph (4), as redesignated by—

6                 (i) inserting “the Deputy Director,”  
7 after “The Director”;

8                 (ii) inserting “Policy” after “Demand  
9 Reduction”;

10                (iii) striking “Deputy Director for  
11 Supply Reduction” and inserting “Deputy  
12 Director for International Drug Policy”;

13                (iv) striking “Associate Deputy Direc-  
14 tor for National Drug Control Policy” and  
15 inserting “Deputy Director for Intergov-  
16 ernmental Relations”;

17                (iv) striking “Director, a Deputy Di-  
18 rector” and inserting “Director or a Dep-  
19 uty Director”; and

20                (v) striking “, or Associate Director”;

21           and

22           (E) in paragraph (6) as redesignated:

23                (i) by redesignating subparagraph (B)  
24 as subparagraph (C);

1 (ii) by inserting after subparagraph

2 (A) the following:

3 “(B) Section 5313 of title 5, United States Code, is  
4 amended by adding at the end ‘Deputy Director of Na-  
5 tional Drug Control Policy’;

6 (iii) in subparagraph (C), as so reded-  
7 igned, by adding “Policy” after “Deputy  
8 Director for Demand Reduction” and by  
9 striking “Supply Reduction” and inserting  
10 “International Drug Policy” after “Deputy  
11 Director for”;

12 (iv) by inserting after subparagraph  
13 (C), as so redesignated, the following:

14 “(D) Section 5314 of title 5, United States Code, is  
15 amended by inserting ‘Deputy Director for Intergovern-  
16 mental Relations, Office of National Drug Control Policy’  
17 after ‘Administrator, Office of Information and Regu-  
18 latory Affairs, Office of Management and Budget’;

19 (v) by striking subparagraph C; and

20 (F) by adding at the end the following:

21 “(7) A Federal officer in the Office of National Drug  
22 Control Policy who is appointed by the President, by and  
23 with the advice and consent of the Senate, may not partici-  
24 pate in Federal election campaign activities, except that

1 such official is not prohibited by this subsection from mak-  
2 ing contributions to individual candidates.”.

3 (3) in subsection (b)—

4 (A) in paragraph (1), by inserting “goals,”  
5 before “objectives”;

6 (B) by striking paragraph (2) and insert-  
7 ing the following:

8 “(2) promulgate the National Drug Control  
9 Strategy and annual Strategy Report in accordance  
10 with section 1005;”;

11 (C) in paragraph (3) by adding “goals,”  
12 after “policies,”;

13 (D) in paragraph (4)(B) by inserting  
14 “goals,” after “the policies,”;

15 (E) in paragraph (5), by inserting “the  
16 formulation and implementation of National  
17 Drug Control Policy and” after “respect to”;  
18 and

19 (F) in paragraph (8)—

20 (i) by striking “second following fiscal  
21 year” and inserting “next budget year  
22 scheduled for formulation under the Budg-  
23 et and Accounting Act of 1921 and each of  
24 the 4 subsequent fiscal years,”; and

25 (ii) by striking “annual”; and

1 (4) in subsection (c)—

2 (A) in paragraph (1)—

3 (i) by striking “transmit” and insert-  
4 ing “submit” after “shall”;

5 (ii) by striking “and” the last place it  
6 appears and inserting “prior to submis-  
7 sion” after “President”;

8 (B) by amending paragraph (2) to read as  
9 follows:

10 “(2)(A) Each Federal Government program man-  
11 ager, agency head, and department head with responsibil-  
12 ities under the National Drug Control Strategy shall  
13 transmit the drug control budget request of the agency  
14 or department to the Director at the same time as such  
15 request is submitted to their superiors (and before submis-  
16 sion to the Office of Management and Budget) in the  
17 preparation of the budget of the President submitted to  
18 Congress under section 1105(a) of title 31, United States  
19 Code.

20 “(B) The Director shall request the head of a depart-  
21 ment or agency to include in the department’s or agency’s  
22 budget submission to the Office of Management and  
23 Budget funding requests for specific initiatives that are  
24 consistent with the President s priorities for the National  
25 Drug Control Strategy and certifications made pursuant

1 to paragraph (3), and the head of the department or agen-  
2 cy shall comply with such a request.

3 “(C) The head of each National Drug Control Pro-  
4 gram agency shall ensure timely development and submis-  
5 sion to the Director of drug control budget requests trans-  
6 mitted pursuant to subsection (c)(2), in such format as  
7 may be designated by the Director with the concurrence  
8 of the Director of the Office of Management and Budg-  
9 et.”.

10 (C) in paragraph (3)—

11 (i) in subparagraph (B), by striking  
12 “and” after “adequate” the last place it  
13 appears;

14 (ii) in subparagraph (C), by striking  
15 the period and inserting “; and”;

16 (D) by redesignating paragraph (4) as sub-  
17 paragraph (D) and striking “the Director  
18 shall”;

19 (E) by striking paragraphs (5), (7), and  
20 (8), and redesignating paragraph (6) as para-  
21 graph (4); and

22 (F) in paragraph (4), as redesignated, by  
23 adding at the end the following:

1       “(C) The Director shall annually submit to Congress  
2 a report describing the approval of any reprogramming or  
3 transfer of appropriated funds pursuant to this section.”;

4           (5) in subsection (d)—

5           (A) in paragraph (1), by striking “up to  
6 75 and such additional” and inserting “such”;

7           (B) in paragraph (5)—

8           (i) by striking “accept and use” and  
9 inserting “accept, use, and solicit”;

10           (ii) by inserting “and gifts” after  
11 “property”; and

12           (iii) by inserting “, and the private  
13 sector, as authorized in section 1002(d)”  
14 before the semicolon;

15           (C) in paragraph (7)—

16           (i) in subparagraph (A), by striking  
17 “and” at the end; and

18           (ii) in subparagraph (B), by adding  
19 “and” at the end; and

20           (iii) by adding at the end the follow-  
21 ing:

22           “(C) commission special studies and re-  
23 ports by a National Drug Control Program  
24 agency, with the concurrence of the head of the  
25 affected agency;” and

1 (D) by striking paragraphs (8) and (9)  
2 and inserting the following:

3 “(8) except to the extent that the Director’s au-  
4 thority under this paragraph is limited in an annual  
5 appropriations Act, and with the concurrence of the  
6 head of the affected agency and upon advance notice  
7 to the Committees of Appropriations of each House  
8 of Congress, transfer funds appropriated to a Na-  
9 tional Drug Control Program agency program, activ-  
10 ity, or function designated by the Director pursuant  
11 to subsection (c) to a different National Drug Con-  
12 trol Program agency program, activity, or function  
13 designated by the Director pursuant to subsection  
14 (c) in an amount that does not exceed 2 percent of  
15 the amount appropriated to either program, activity,  
16 or function;

17 “(9) issue to the head of a National Drug Con-  
18 trol Program agency a funds control notice described  
19 in subsection (f) to ensure compliance with the Na-  
20 tional Drug Control Program; and

21 “(10) participate in the drug certification proc-  
22 ess pursuant to section 490 of the Foreign Assist-  
23 ance Act of 1961 (22 U.S.C. 2291j).”;

24 (6) by striking the second subsection designated  
25 as subsection (f).

1 (d) COORDINATION WITH EXECUTIVE BRANCH DE-  
2 PARTMENTS AND AGENCIES.—Section 1004 (21 U.S.C.  
3 1503) is amended—

4 (1) by amending the section heading to read as  
5 follows:

6 **“SEC. 1004. COORDINATION WITH EXECUTIVE BRANCH DE-**  
7 **PARTMENTS AND AGENCIES IN SUPPLY RE-**  
8 **DUCTION, DEMAND REDUCTION, AND INTER-**  
9 **GOVERNMENTAL RELATIONS.”;**

10 (2) in subsection (a)(1)—

11 (A) by inserting “cooperate with and” be-  
12 fore “provide”; and

13 (B) by inserting “and the annual report to  
14 Congress” before the period.

15 (e) DEVELOPMENT AND SUBMISSION OF NATIONAL  
16 DRUG CONTROL STRATEGY.—Section 1005 (21 U.S.C.  
17 1504) is amended to read as follows:

18 **“SEC. 1005. DEVELOPMENT, SUBMISSION, IMPLEMENTA-**  
19 **TION, AND ASSESSMENT OF NATIONAL DRUG**  
20 **CONTROL STRATEGY.**

21 **“(a) TIMING, CONTENT, AND PROCESS FOR DEVEL-**  
22 **OPMENT AND SUBMISSION OF THE NATIONAL DRUG CON-**  
23 **TROL STRATEGY.—**

24 **“(1) Not later than February 1, 1997, the**  
25 **President shall submit to the Congress a National**

1 Drug Control Strategy, which shall set forth a com-  
2 prehensive 10-year plan for reducing drug abuse and  
3 its consequences in the United States by limiting the  
4 availability of and reducing the demand for illegal  
5 drugs. Any part of such strategy that involves infor-  
6 mation properly classified under criteria established  
7 by an Executive order shall be presented to Congress  
8 separately from the rest of the strategy.

9 “(2) The National Drug Control Strategy sub-  
10 mitted under paragraph (1) shall include—

11 “(A) comprehensive, research-based, long-  
12 range goals for reducing drug abuse and the  
13 consequences of drug abuse in the United  
14 States;

15 “(B) measurable objectives to accomplish  
16 long-term goals;

17 “(C) 5-year projections for program and  
18 budget priorities; and

19 “(D) a review of State, local, and private  
20 sector drug control activities to ensure that the  
21 United States pursues well-coordinated and ef-  
22 fective drug control at all levels of government.

23 “(3) CONSULTATIONS.—

1           “(A) In developing and effectively imple-  
2           menting the National Drug Control Strategy,  
3           the Director shall consult with—

4                   “(i) the heads of the National Drug  
5                   Control Program agencies;

6                   “(ii) Congress;

7                   “(iii) State and local officials;

8                   “(iv) private citizens and organiza-  
9                   tions with experience and expertise in de-  
10                  mand reduction; and

11                  “(v) private citizens and organizations  
12                  with experience and expertise in supply re-  
13                  duction;

14                  “(B) The National Drug Control Strategy  
15                  and each annual Strategy Report shall indicate  
16                  the persons consulted under this paragraph.

17           “(b) ANNUAL STRATEGY REPORT.—Not later than  
18           February 1, 1998, and on February 1 of each year there-  
19           after, the President shall submit to Congress an annual  
20           report on the progress in implementing the Strategy under  
21           subsection (a), which shall include—

22                   “(1) an assessment of the Federal effectiveness  
23                   in achieving the Strategy goals and objectives using  
24                   the performance measurement system described in  
25                   subsection (c);

1 “(2) any modifications of the Strategy;

2 “(3) an assessment of how the budget proposal  
3 submitted under section 1003(e) (21 U.S.C.  
4 1502(e)) is intended to implement the strategy and  
5 whether the funding levels contained in such pro-  
6 posal are sufficient to implement such strategy;

7 “(4) an assessment of current drug use and  
8 availability, impact of drug use, and treatment avail-  
9 ability. This assessment will include—

10 “(A) estimates of drug prevalence and fre-  
11 quency of use as measured by national, State,  
12 and local surveys of illicit drug use and by  
13 other special studies of—

14 “(i) casual and chronic drug use;

15 “(ii) high-risk populations, including  
16 school dropouts, the homeless and tran-  
17 sient, arrestees, parolees, probationers, and  
18 juvenile delinquents; and

19 “(iii) drug use in the workplace and  
20 the productivity lost by such use;

21 “(B) an assessment of the reduction of  
22 drug availability against an ascertained base-  
23 line, as measured by—

24 “(i) the quantities of cocaine, heroin,  
25 marijuana, methamphetamine, and other

1 drugs available for consumption in the  
2 United States;

3 “(ii) the amount of marijuana, co-  
4 caine, and heroin entering the United  
5 States;

6 “(iii) the number of hectares of mari-  
7 juana, poppy, and coca cultivated and de-  
8 stroyed;

9 “(iv) the number of metric tons of  
10 marijuana, heroin, and cocaine seized;

11 “(v) the number of cocaine and meth-  
12 amphetamine processing laboratories de-  
13 stroyed;

14 “(vi) changes in the price and purity  
15 of heroin and cocaine;

16 “(vii) the amount and type of con-  
17 trolled substances diverted from legitimate  
18 retail and wholesale sources; and

19 “(viii) the effectiveness of Federal  
20 technology programs at improving drug de-  
21 tection capabilities in interdiction, and at  
22 United States ports of entry;

23 “(C) an assessment of the reduction of the  
24 consequences of drug use and availability, which  
25 shall include estimation of—

1           “(i) burdens drug users placed on  
2 hospital emergency departments in the  
3 United States, such as the quantity of  
4 drug-related services provided;

5           “(ii) the annual national health care  
6 costs of drug use, including costs associ-  
7 ated with people becoming infected with  
8 the human immuno-deficiency virus and  
9 other infectious diseases as a result of  
10 drug use;

11           “(iii) the extent of drug-related crime  
12 and criminal activity; and

13           “(iv) the contribution of drugs to the  
14 underground economy, as measured by the  
15 retail value of drugs sold in the United  
16 States;

17           “(D) a determination of the status of drug  
18 treatment in the United States, by assessing—

19           “(i) public and private treatment ca-  
20 pacity within each State, including infor-  
21 mation on the treatment capacity available  
22 in relation to the capacity actually used;

23           “(ii) the extent, within each State, to  
24 which treatment is available;

1                   “(iii) the number of drug users the  
2                   Director estimates could benefit from  
3                   treatment; and

4                   “(iv) the specific factors that restrict  
5                   the availability of treatment services to  
6                   those seeking it and proposed administra-  
7                   tive or legislative remedies to make treat-  
8                   ment available to those individuals;

9                   “(E) a review of the research agenda of  
10                  the Counter-Drug Technology Assessment Cen-  
11                  ter to reduce the availability and abuse of  
12                  drugs;

13                  “(5) an assessment of private sector initiatives  
14                  and cooperative efforts between the Federal Govern-  
15                  ment and State and local governments for drug con-  
16                  trol.

17                  “(c) PERFORMANCE MEASUREMENT SYSTEM.—The  
18                  Director shall include with the annual Strategy Report a  
19                  description of the national drug control performance  
20                  measurement system, designed in consultation with af-  
21                  fected National Drug Control Program agencies, that—

22                         “(1) develops performance objectives, measures,  
23                         and targets for each National Drug Control Strategy  
24                         goal and objective;

1           “(2) revises performance objectives, targets,  
2           and measures to conform with National Drug Con-  
3           trol Program Agency budgets;

4           “(3) identifies major programs and activities of  
5           the National Drug Control Program Agencies that  
6           support the goals and objectives of the National  
7           Drug Control Strategy;

8           “(4) evaluates implementation of major pro-  
9           gram activities supporting the National Drug Con-  
10          trol Strategy developed under this section;

11          “(5) monitors consistency between the drug-re-  
12          lated goals and objectives of the National Drug Con-  
13          trol Program agencies and ensures that drug control  
14          agency goals and budgets support and are fully con-  
15          sistent with the National Drug Control Strategy;  
16          and

17          “(6) coordinates the development and imple-  
18          mentation of national drug control data collection  
19          and reporting systems to support policy formulation  
20          and performance measurement, including—

21                 “(A) an assessment of the quality of cur-  
22                 rent drug use measurement instruments and  
23                 techniques to measure supply reduction and de-  
24                 mand reduction activities;



1 making such a designation and in order to provide Federal  
2 assistance to the area so designated, the Director may—

3           “(1) obligate such sums as appropriated for the  
4 High Intensity Drug Trafficking Area Program;

5           “(2) direct the temporary reassignment of Fed-  
6 eral personnel to such area, subject to the approval  
7 of the Secretary of the department or head of the  
8 agency that employs such personnel;

9           “(3) take any other action authorized under  
10 section 1003 to provide increased Federal assistance  
11 to such areas;

12           “(4) coordinate actions under this paragraph  
13 with State and local officials; and

14           “(5) in consultation with affected National  
15 Drug Control Policy agencies, promulgate such regu-  
16 lations for the effective implementation of the High  
17 Intensity Drug Trafficking Areas Program.

18           “(c) When considering the designation of an area  
19 under this section as a high intensity drug trafficking area,  
20 the Director shall consider, in addition to such other cri-  
21 teria as the Director considers to be appropriate, the ex-  
22 tent to which—

23           “(1) the area is a center of illegal drug produc-  
24 tion, manufacturing, importation, or distribution;

1           “(2) State and local law enforcement agencies  
2           have committed resources to respond to the drug  
3           trafficking problem in the area, thereby indicating a  
4           determination to respond aggressively to the prob-  
5           lem;

6           “(3) State and local demand reduction agencies  
7           have committed resources to respond to drug abuse  
8           in the area, thereby indicating a determination to re-  
9           spond to the problem;

10           “(4) drug-related activities in the area are hav-  
11           ing a harmful impact in other areas of the country;  
12           and

13           “(5) a significant increase in allocation of Fed-  
14           eral resources is necessary to respond adequately to  
15           drug-related activities in the area.”.

16           (g) COUNTER-DRUG TECHNOLOGY ASSESSMENT  
17 CENTER.—Section 1008 (21 U.S.C. 1505) is amended to  
18 read as follows:

19 **“SEC. 1008. COUNTER-DRUG TECHNOLOGY ASSESSMENT**  
20 **CENTER.**

21           “(a) ESTABLISHMENT.—There is established within  
22 the Office the Counter-Drug Technology Assessment Cen-  
23 ter (in this section referred to as the ‘Center’). The Center  
24 shall operate under the authority of the Director of Na-  
25 tional Drug Control Policy and shall serve as the central

1 counter-drug technology research and development organi-  
2 zation of the United States Government.

3 “(b) DIRECTOR OF TECHNOLOGY.—There shall be at  
4 the head of the Center the Director of Technology, who  
5 shall be appointed by the Director of National Drug Con-  
6 trol Policy from among individuals qualified and distin-  
7 guished in the area of science, medicine, engineering, or  
8 technology.

9 “(c) ADDITIONAL RESPONSIBILITIES OF THE DIREC-  
10 TOR OF NATIONAL DRUG CONTROL POLICY.—

11 “(1) The Director, acting through the Director  
12 of Technology shall—

13 “(A) identify and define the short-, me-  
14 dium-, and long-term scientific and techno-  
15 logical needs of Federal, State, and local drug  
16 supply reduction agencies, including—

17 “(i) advanced surveillance, tracking,  
18 and radar imaging;

19 “(ii) electronic support measures;

20 “(iii) communications;

21 “(iv) data fusion, advanced computer  
22 systems, and artificial intelligence; and

23 “(v) chemical, biological, radiological  
24 (including neutron, electron, and graviton),  
25 and other means of detection;

1           “(B) identify demand reduction basic and  
2 applied research needs and initiatives, in con-  
3 sultation with affected National Drug Control  
4 Program agencies, including—

5                   “(i) improving treatment through  
6 neuroscientific advances;

7                   “(ii) improving the transfer of bio-  
8 medical research to the clinical setting, and

9                   “(iii) developing new advances in drug  
10 abuse prevention programming;

11                   “(iv) in consultation with the National  
12 Institute on Drug Abuse, and through  
13 interagency agreements or grants, examine  
14 addiction and rehabilitation research and  
15 the application of technology to expanding  
16 the effectiveness or availability of drug  
17 treatment;

18           “(C) make a priority ranking of such needs  
19 identified in subparagraphs (A) and (B) accord-  
20 ing to fiscal and technological feasibility, as  
21 part of a National Counter-Drug Enforcement  
22 Research and Development Program;

23           “(D) oversee and coordinate counter-drug  
24 technology initiatives with related activities of  
25 other Federal civilian and military departments;

1           “(E) provide support to the development  
2           and implementation of the national drug control  
3           performance measurement system; and

4           “(F) pursuant to the authority of the Di-  
5           rector of National Drug Control Policy under  
6           section 1003 (21 U.S.C. 1502), submit requests  
7           to Congress for the reprogramming or transfer  
8           of funds appropriated for counter-drug tech-  
9           nology research and development.

10          “(2) The authority granted to the Director  
11          under this section shall not extend to the award of  
12          contracts, management of individual projects, or  
13          other operational activities.

14          “(d) ASSISTANCE AND SUPPORT TO OFFICE OF NA-  
15          TIONAL DRUG CONTROL POLICY.—The Department of  
16          Defense and the Department of Health and Human Serv-  
17          ices shall, to the fullest extent possible, render assistance  
18          and support to the Office and its Director, in the conduct  
19          of counter-drug technology assessment.”.

20          (h) TERMINATION OF OFFICE OF NATIONAL DRUG  
21          CONTROL POLICY.—Section 1009 (42 U.S.C. 1506) is  
22          amended to read as follows:

1 **“SEC. 1009. TERMINATION OF OFFICE OF NATIONAL DRUG**  
2 **CONTROL POLICY.**

3 “Effective on September 30, 2009, this subtitle and  
4 the amendments made by this subtitle are repealed.”.

5 (i) **AUTHORIZATION OF APPROPRIATIONS.**—Section  
6 1011 (21 U.S.C. 1508) is amended to read as follows:

7 **“SEC. 1011. AUTHORIZATION OF APPROPRIATIONS.**

8 “There are authorized to be appropriated to carry out  
9 this subtitle, to remain available until expended, such  
10 sums as may be necessary for each of the fiscal years  
11 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006,  
12 2007, 2008, and 2009.”.

13 (j) **ESTABLISHMENT OF SPECIAL FORFEITURE**  
14 **FUND.**—Section 6073 of the Asset Forfeiture Amend-  
15 ments Act of 1988 (21 U.S.C. 1509) is amended—

16 (1) in subsection (b),

17 (A) by striking “section 524(c)(9)” and in-  
18 sserting “section 524(c)(8)”;

19 (B) by striking “section 9307(g)” and in-  
20 sserting “section 9703(g)”;

21 (2) in subsection (e), by striking “strategy” and  
22 inserting “Strategy”.

○